



Abridged Australian Reimbursement & Market Analysis Monitor[®]

FEBRUARY 2007

SUMMARY OF INFORMATION FROM THE MOST RECENT PBAC MEETING

Meeting date – November 2006

No. of submissions – 62

Submission type	% of total	% approved
New class ¹	9.7	50.0
New chemical entity	17.7	45.5
New indication	8.1	60.0
New dosage form	4.8	100
Fixed-dose combination	12.9	100
New formulation	4.8	66.7
Change in wording/restriction	24.2	86.7
New brands	4.8	100
Other	12.9	75.0
Total	100	74.2

¹Denotes World Health Organizations ATC (anatomical, therapeutic, chemical) classification of level 4 or higher, and a new chemical entity that has a different mechanism of action.

New classes,¹ new chemical entities and new indications

No. of submissions – 23

Analysis type	% of total	% approved
Cost-effectiveness analysis ²	73.9	29.4
Cost minimisation analysis ³	26.1	100

¹Denotes World Health Organizations ATC (anatomical, therapeutic, chemical) classification of level 4 or higher, and a new chemical entity that has a different mechanism of action.

²High costs and superior outcomes.

³Equal outcomes and equal or lower costs. When the PBAC does not accept claims of superior safety or efficacy, submissions are listed as cost-minimisation.

SUMMARY OF CHANGES TO THE SCHEDULE OF PHARMACEUTICAL BENEFITS

Listings – December 2006

No. of listings – 55

Type of listing	% of total
New class	0
New chemical entity	12.7
New indication	7.2
New dosage form	7.3
Fixed-dose combination	10.9
New formulation	5.5
New brands	50.9
Other	5.5
Total	100

Time to listing – December 2006

New classes,¹ new chemical entities and new indications

Average time from ADEC meeting approving registration to positive PBAC recommendation	Average time from positive PBAC recommendation to listing	% listed on time
24 months	5.7 months	82

¹Denotes World Health Organizations ATC (anatomical, therapeutic, chemical) classification of level 4 or higher, and a new chemical entity that has a different mechanism of action.

Pricing – February 2007

	Impact on PBS (value)
Price increase	\$3 358 000
Price decrease	\$36 907 000
Net impact	-\$33 549 000

Does not include chemotherapy drugs, Section 100 changes, changes in brand price premiums, therapeutic group premiums or special patient contributions.
Impact = (change in DPMQ – Dispensing fee) x volume preceeding 12 months

IMS Pricing & Market Access team, formerly known as M-TAG, assists clients in reimbursement and pricing applications, economic evaluations, critical reviews and meta-analyses, and marketing services. Our focus is to remain at the forefront of health care research and to assist clients in applying the most technologically innovative approach to achieve their objectives.

The Abridged Australian Drug Reimbursement & Market Analysis Monitor[®] is a brief summary which may be circulated freely. This newsletter is supplied 'as is', and we make no representation nor warranty regarding its use. An in-depth report on the reimbursement environment is provided through subscription to the Australian Drug Reimbursement and Market Analysis Monitor[®]. To enquire about a subscription, please contact Jean-Claude Balducci on (02)9805 6933 or email: jbalducci@au.imshealth.com